About diaDexus

diaDexus Mission
diaDexus makes a difference by developing innovative products to detect cancer and cardiovascular disease.

Company Overview
diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to certain diagnostic intellectual property, and Incyte contributed free access to its databases.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

diaDexus' lead product, the PLAC® test, is a blood test that measures the concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel risk factor for cardiovascular disease. The PLAC test is the only blood test cleared by the FDA as an aid in determining risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Numerous published or presented studies, involving more than 20,000 subjects, highlight Lp-PLA2 as an important risk factor for cardiovascular disease. For more information regarding the PLAC test, visit www.plactest.com.

In addition to developing and marketing the PLAC test, diaDexus owns or has exclusively licensed patents or patent applications covering hundreds of novel molecular targets associated with cancer. The company is developing simple blood tests to detect early stage cancer in otherwise healthy individuals, with the most advanced diagnostic development targeting detection of ovarian cancer. Additionally, diaDexus’ oncology prognostics program leverages genomic and nucleic acid technological expertise, with the goal of improving the prognosis and staging of breast, colorectal and other cancers.